evidence: High-dose transdermal nicotine in Parkinson's disease patients: a randomized, open-label, blinded-endpoint evaluation phase 2 study - PMID: 28960663 - DOI: 10.1111/ene.13474 [...] Background and purpose: Studies of the effects of nicotine on motor symptoms in Parkinson's disease (PD) brought out discordant results. The aim of the present study was to evaluate the efficacy and safety of high doses of transdermal nicotine on motor symptoms in PD. [...] Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease.Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):31-9. doi: 10.1016/S0278-5846(03)00172-6. Prog Neuropsychopharmacol Biol Psychiatry. 2004. PMID: 14687854 Clinical Trial.